CA2258755A1 - Therapie genique pour le traitement de l'obesite - Google Patents

Therapie genique pour le traitement de l'obesite Download PDF

Info

Publication number
CA2258755A1
CA2258755A1 CA 2258755 CA2258755A CA2258755A1 CA 2258755 A1 CA2258755 A1 CA 2258755A1 CA 2258755 CA2258755 CA 2258755 CA 2258755 A CA2258755 A CA 2258755A CA 2258755 A1 CA2258755 A1 CA 2258755A1
Authority
CA
Canada
Prior art keywords
leptin
mice
gene
adenovirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2258755
Other languages
English (en)
Inventor
Manal A. Morsy
Ming Cheng Gu
Jing Zhao
C. Thomas Caskey
Stefan Kochanek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615788.8A external-priority patent/GB9615788D0/en
Application filed by Individual filed Critical Individual
Publication of CA2258755A1 publication Critical patent/CA2258755A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La thérapie génique peut traiter l'obésité chez les mammifères. On administre un gène de régulation de l'obésité à un mammifère. De préférence, le gène code la leptine ou un récepteur de la leptine. La protéine qui est administrée et exprimée in vivo est plus efficace que la protéine qui est injectée dans l'animal.
CA 2258755 1996-06-20 1997-06-20 Therapie genique pour le traitement de l'obesite Abandoned CA2258755A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US2081396P 1996-06-20 1996-06-20
US60/020,813 1996-06-20
GBGB9615788.8A GB9615788D0 (en) 1996-07-26 1996-07-26 Gene therapy for obesity
GB9615788.8 1996-07-26
US2675396P 1996-09-26 1996-09-26
US60/020,753 1996-09-26

Publications (1)

Publication Number Publication Date
CA2258755A1 true CA2258755A1 (fr) 1997-12-24

Family

ID=27268405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2258755 Abandoned CA2258755A1 (fr) 1996-06-20 1997-06-20 Therapie genique pour le traitement de l'obesite

Country Status (4)

Country Link
EP (1) EP0954579A1 (fr)
JP (1) JP2002514904A (fr)
CA (1) CA2258755A1 (fr)
WO (1) WO1997048806A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
CA2258504A1 (fr) * 1996-06-20 1997-12-24 Merck & Co., Inc. Therapie genique de l'obesite
EP1084236A4 (fr) * 1998-06-09 2003-04-02 Merck & Co Inc Nouveaux vecteurs adenoviraux utilises en therapie genique
ATE278952T1 (de) * 1998-07-28 2004-10-15 Vlaams Interuniv Inst Biotech Leptin vermittelte geninduktion
WO2000046360A1 (fr) * 1999-02-04 2000-08-10 Merck & Co., Inc. Amelioration du systeme vecteur dependant d'un assistant-dependant pour la therapie genique
EP1889914A1 (fr) * 1999-02-19 2008-02-20 Engene, Inc. Compositions de thérapie génétique pour le diabète
US7132277B1 (en) 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
EP1290206A2 (fr) * 2000-06-09 2003-03-12 University of Florida Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques
WO2002092786A2 (fr) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University Systeme de vecteurs adenoviraux dependants d'un auxiliaire, et methodes d'utilisation
CU23102A1 (es) * 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
JP2012508242A (ja) 2008-11-04 2012-04-05 ニコラオス テザプシディス 神経原線維のもつれ及びアミロイドβの蓄積に起因する進行性認知機能障害を治療するためのレプチン組成物及び方法
WO2013186398A1 (fr) * 2012-06-15 2013-12-19 Fondazione Telethon Tfeb destiné à être utilisé dans le traitement de l'obésité ou du syndrome métabolique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656544B2 (en) * 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JP2000507081A (ja) * 1995-05-08 2000-06-13 カイロン コーポレイション 肥満症を治療するための核酸
CA2247503A1 (fr) * 1996-03-01 1997-09-04 Amgen Inc. Compositions de proteine ob canine et procedes

Also Published As

Publication number Publication date
JP2002514904A (ja) 2002-05-21
EP0954579A1 (fr) 1999-11-10
WO1997048806A1 (fr) 1997-12-24

Similar Documents

Publication Publication Date Title
CA2258755A1 (fr) Therapie genique pour le traitement de l'obesite
Michou et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression
US6447768B1 (en) Methods of gene therapy with a DNA sequence encoding NOS
US6174527B1 (en) Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
EP0787200B1 (fr) Adenovirus ameliore et ses procedes d'utilisation
AU727992B2 (en) Adenoviral vectors comprising a modified E4 region but retaining E4ORF3
US6001816A (en) Gene therapy for leptin deficiency
Nalbantoglu et al. Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle
JP4733795B2 (ja) ヒツジアデノウイルスベクターを用いた遺伝子治療
EP0974668B1 (fr) Utilisation des cadres de lecture de la région E4 pour l'amélioration de l'expression de gènes
EP0710288A1 (fr) Vecteurs adenoviraux pour le traitement de l'hemophilie
AU5694299A (en) Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
US8883493B2 (en) Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
KR20210030965A (ko) 다논병을 치료하기 위한 유전자 요법 벡터
KR20210125999A (ko) 다논병 치료를 위한 유전자 요법 벡터
US6630346B1 (en) Gene therapy for obesity
EP0921820A1 (fr) Therapie genique de l'obesite
US20030215423A1 (en) Gene therapy for obesity
JP2002522558A (ja) エリスロポエチンをコードするアデノウイルスベクター及び遺伝子治療におけるそれらの使用
US20020055173A1 (en) Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
EP1084236A1 (fr) Nouveaux vecteurs adenoviraux utilises en therapie genique
EP1016727A1 (fr) Thérapie génique ayant pour but la promotion de l' angiogenèse
JP2005336199A5 (fr)
KR19990072793A (ko) Ｄｎａ서열의유전자수송을위한아데노바이러스전달벡터

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead